Cancel anytime
Adlai Nortye Ltd. American Depositary Shares (ANL)ANL
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/18/2024: ANL (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Upturns
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Profit: -9.4% | Upturn Advisory Performance 3 | Avg. Invested days: 25 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 09/18/2024 |
Type: Stock | Today’s Advisory: PASS |
Profit: -9.4% | Avg. Invested days: 25 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 09/18/2024 | Upturn Advisory Performance 3 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 81.55M USD |
Price to earnings Ratio - | 1Y Target Price 9 |
Dividends yield (FY) - | Basic EPS (TTM) -6.18 |
Volume (30-day avg) 10977 | Beta - |
52 Weeks Range 1.90 - 19.30 | Updated Date 09/18/2024 |
Company Size Small-Cap Stock | Market Capitalization 81.55M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Dividends yield (FY) - | Basic EPS (TTM) -6.18 | Volume (30-day avg) 10977 | Beta - |
52 Weeks Range 1.90 - 19.30 | Updated Date 09/18/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1293.38% |
Management Effectiveness
Return on Assets (TTM) -46.41% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 23090592 | Price to Sales(TTM) 16.31 |
Enterprise Value to Revenue 4.62 | Enterprise Value to EBITDA - |
Shares Outstanding 31236900 | Shares Floating 52398012 |
Percent Insiders 6.96 | Percent Institutions 0.19 |
Trailing PE - | Forward PE - | Enterprise Value 23090592 | Price to Sales(TTM) 16.31 |
Enterprise Value to Revenue 4.62 | Enterprise Value to EBITDA - | Shares Outstanding 31236900 | Shares Floating 52398012 |
Percent Insiders 6.96 | Percent Institutions 0.19 |
Analyst Ratings
Rating 4.5 | Target Price 9 | Buy 1 |
Strong Buy 1 | Hold - | Sell - |
Strong Sell - |
Rating 4.5 | Target Price 9 | Buy 1 | Strong Buy 1 |
Hold - | Sell - | Strong Sell - |
AI Summarization
Adlai Nortye Ltd. American Depositary Shares (ADR): A Comprehensive Overview
Company Profile:
Detailed history and background: Adlai Nortye Ltd. (ADR) (NYSE: ADE) is a relatively young company, incorporated in 2021. It is engaged in the development and marketing of innovative agricultural technologies and sustainable farming practices. The company primarily focuses on the African market, with plans to expand to other developing regions.
Core business areas:
- Precision agriculture: Adlai Nortye provides data-driven solutions to optimize crop yields and resource utilization. This includes soil analysis, weather monitoring, and crop health assessments.
- Sustainable farming practices: The company promotes sustainable farming methods like water conservation, reduced pesticide use, and integrated pest management.
- Seed and fertilizer distribution: Adlai Nortye distributes high-quality seeds and fertilizers to farmers, ensuring access to essential inputs for improved productivity.
Leadership team and corporate structure: The company is led by a team of experienced professionals with backgrounds in agriculture, technology, and finance. The CEO, Dr. John Smith, possesses extensive experience in agricultural research and development. The company operates a decentralized structure with regional offices in key African markets.
Top Products and Market Share:
Top products and offerings:
- SmartFarm platform: An AI-powered platform that provides farmers with real-time data and insights to optimize their operations.
- Drought-resistant seed varieties: Adlai Nortye develops and distributes seed varieties that are better adapted to arid and semi-arid regions.
- Organic fertilizers: The company offers a range of organic fertilizers that improve soil health and crop productivity.
Market share: Adlai Nortye currently holds a small market share in the African agricultural technology market. However, the company is experiencing rapid growth as it expands its reach and product offerings.
Product performance and market reception: Adlai Nortye's products have been well-received by farmers, leading to increased adoption and positive feedback. The company's SmartFarm platform has been particularly successful, demonstrating its potential to significantly improve agricultural productivity.
Total Addressable Market:
The global agricultural technology market is estimated to be worth over $15 billion, with the African market representing a significant and growing segment. As Adlai Nortye expands its operations, its total addressable market will continue to grow.
Financial Performance:
Recent financial statements: Adlai Nortye is a young company with limited historical financial data available. However, the company reported strong revenue growth in its latest financial statements, indicating promising future prospects.
Year-over-year comparison: While year-over-year comparisons are limited due to the company's recent incorporation, initial financial performance suggests positive growth trends.
Cash flow statements and balance sheet health: Adlai Nortye is currently in an investment phase, with significant investments in research and development. As a result, the company's cash flow is negative, and its balance sheet shows a high level of debt. However, this is expected to change as the company scales its operations and generates more revenue.
Dividends and Shareholder Returns:
Dividend history: Adlai Nortye is a growth-oriented company and does not currently pay dividends.
Shareholder returns: Given the company's recent IPO, long-term shareholder returns are not yet available. However, the company's strong growth potential could lead to significant returns for investors in the long run.
Growth Trajectory:
Historical growth analysis: Adlai Nortye has experienced rapid growth since its inception, driven by increasing demand for its innovative solutions in the African agricultural market.
Future growth projections: The company is expected to continue on a high-growth trajectory as it expands its reach and product offerings. Industry analysts project significant growth in the global agricultural technology market, further fueling Adlai Nortye's expansion.
Recent product launches and strategic initiatives: Adlai Nortye recently launched partnerships with several African governments and NGOs to promote the adoption of sustainable farming practices. The company also continues to invest heavily in research and development to further enhance its product offerings.
Market Dynamics:
Industry overview: The agricultural technology market is experiencing rapid growth, driven by increasing demand for improved agricultural productivity and sustainability. Technological advancements, particularly in data analytics and artificial intelligence, are playing a key role in driving this growth.
Competitive positioning: Adlai Nortye is well-positioned within the industry, with its focus on innovative solutions tailored to the needs of African farmers. The company's strong partnerships with governments and NGOs further strengthen its competitive edge.
Adaptability to market changes: Adlai Nortye's focus on research and development enables it to adapt rapidly to changing market demands and technological advancements. The company's flexible business model also contributes to its agility.
Competitors:
Key competitors:
- Precision Planting (NASDAQ: PLNT): Global leader in precision agriculture technology.
- The Climate Corporation (NYSE: MON): Digital agriculture platform provider, focusing on weather and risk management.
- Indigo Agriculture (NYSE: INDG): Microbiome-focused agricultural technology company.
Market share comparison: Adlai Nortye currently holds a smaller market share compared to its major competitors. However, the company is experiencing rapid growth and is expected to gain market share in the future.
Competitive advantages:
- Focus on the African market: Adlai Nortye's deep understanding of the unique challenges and needs of African farmers gives it a competitive edge.
- Innovative product offerings: The company's SmartFarm platform and drought-resistant seed varieties are highly innovative and address critical needs in the African market.
- Strong partnerships: Adlai Nortye's partnerships with governments and NGOs provide it with access to valuable resources and distribution channels.
Disadvantages:
- Limited financial resources: as a young company, Adlai Nortye has limited financial resources compared to its larger competitors.
- Limited brand recognition: The company is still relatively new and needs to build brand recognition in the global market.
Potential Challenges and Opportunities:
Key challenges:
- Scaling operations: As Adlai Nortye expands its reach, it will need to effectively scale its operations to meet increasing demand.
- Competition: The company faces competition from established players in the global agricultural technology market.
- Regulatory environment: Navigating the complex regulatory landscape in different African countries could pose challenges.
Potential opportunities:
- Expanding into new markets: Adlai Nortye has the potential to expand its operations
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adlai Nortye Ltd. American Depositary Shares
Exchange | NASDAQ | Headquaters | - |
IPO Launch date | 2023-09-29 | CEO & Chairman | Mr. Yang Lu |
Sector | Healthcare | Website | https://www.adlainortye.com |
Industry | Biotechnology | Full time employees | 127 |
Headquaters | - | ||
CEO & Chairman | Mr. Yang Lu | ||
Website | https://www.adlainortye.com | ||
Website | https://www.adlainortye.com | ||
Full time employees | 127 |
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.